Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Gastric Cancer

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Gastroenterology

Show all topics

DOI

10.1007/s10120-018-00909-5

License

CC-BY

Other Formats

PDF